Korean Market
OWNR
GemVax & KAEL
★

No change in stake at 25.90%, but pledged shares increase to 4,699,674 (10.62%)

 
EXCH
GemVax & KAEL
★★

Major shareholder Gem & Company pledges 84.7% of holdings; stake could drop to 1.88% if executed

 
MATR
GemVax & KAEL
★

Decision to Issue Convertible Bonds - Put Option Available After 1 Year, Transfer Restricted for 1 Year

 
EXCH
GemVax & KAEL
★★

Supreme Court Damage Lawsuit Withdrawn via Settlement - 17.8 Billion Won Settlement and Convertible Bond Issuance

 
EXCH
GemVax & KAEL
★★

Acquisition of 35.85% Stake in BioVille for 12.4 Billion Won via Litigation Settlement

 
MATR
GemVax & KAEL
★★

Decision to Issue Convertible Bonds for Supreme Court Lawsuit Settlement

 
EXCH
GemVax & KAEL
★★★

Major Shareholder Additional Pledge and Financial Risk Intensification

 
PERI
GemVax & KAEL
★

GemVax&KAEL: 1Q26 Consolidated Operating Loss of 7.6B KRW, Net Loss of 14.9B KRW; Debt Ratio Improves to 88.6%; GV1001 PSP Conditional Approval Filed

 
EXCH
GemVax & KAEL
★★★

[Correction] Largest Shareholder Extends Pledge, Pledge Ratio 82.9% and Debtor's Deteriorating Finances

 
OWNR
GemVax & KAEL
★

New Large Shareholding Report Due to Affiliation with Samsung Pharmaceutical

 
EXCH
GemVax & KAEL
★★★★

Withdrawal of 27.08 Billion Won Payment Order Application Eliminates Potential Liability

 
EXCH
GemVax & KAEL
★

Voluntary Disclosure of 14th Unsecured Private Convertible Bond Issuance (KRW 7.4B)

 
EXCH
GemVax & KAEL
★

Result of 15th Convertible Bond Issuance of KRW 8.9 Billion (Private, Unlisted)

 
EXCH
GemVax & KAEL
★★★

Major shareholder Gem&Company pledges 83% of shares, debt 87.99B won, equity -75.21B won